Investors purchased shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading hours on Friday. $112.26 million flowed into the stock on the tick-up and $80.44 million flowed out of the stock on the tick-down, for a money net flow of $31.82 million into the stock. Of all stocks tracked, Becton, Dickinson and had the 22nd highest net in-flow for the day. Becton, Dickinson and traded down ($5.25) for the day and closed at $219.23

Several equities analysts have commented on BDX shares. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company restated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC restated an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Royal Bank Of Canada restated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Finally, BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $213.47.

The firm has a market cap of $49,870.00, a PE ratio of 23.33, a price-to-earnings-growth ratio of 1.73 and a beta of 1.04. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same quarter last year, the firm posted $2.12 earnings per share. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. equities analysts forecast that Becton, Dickinson and Company will post 10.63 EPS for the current year.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the sale, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last three months, insiders sold 60,650 shares of company stock worth $12,223,970. Insiders own 1.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Cipher Capital LP acquired a new stake in shares of Becton, Dickinson and in the 1st quarter valued at $2,574,000. Victory Capital Management Inc. raised its holdings in shares of Becton, Dickinson and by 7.1% in the first quarter. Victory Capital Management Inc. now owns 13,676 shares of the medical instruments supplier’s stock valued at $2,509,000 after buying an additional 902 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of Becton, Dickinson and by 6.1% in the first quarter. Blair William & Co. IL now owns 29,850 shares of the medical instruments supplier’s stock valued at $5,467,000 after buying an additional 1,703 shares during the last quarter. Cibc World Markets Corp raised its holdings in shares of Becton, Dickinson and by 52.7% in the first quarter. Cibc World Markets Corp now owns 22,240 shares of the medical instruments supplier’s stock valued at $4,080,000 after buying an additional 7,674 shares during the last quarter. Finally, Patton Albertson Miller Group LLC raised its holdings in shares of Becton, Dickinson and by 7.4% in the first quarter. Patton Albertson Miller Group LLC now owns 1,386 shares of the medical instruments supplier’s stock valued at $250,000 after buying an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 86.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/traders-buy-becton-dickinson-and-company-bdx-on-weakness/1694214.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.